United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $237.91, for a total transaction of $856,476.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,928.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Trading Up 0.4 %

Shares of UTHR stock opened at $237.93 on Friday. The stock’s fifty day moving average is $231.71 and its two-hundred day moving average is $228.55. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. The firm has a market capitalization of $11.20 billion, a P/E ratio of 11.99 and a beta of 0.52. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.67 EPS. Research analysts expect that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on UTHR shares. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Wells Fargo & Company increased their target price on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. SVB Leerink initiated coverage on United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $292.67.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of UTHR. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the 1st quarter worth $32,000. GAMMA Investing LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth $43,000. Neo Ivy Capital Management purchased a new position in shares of United Therapeutics during the 2nd quarter worth $48,000. Atlas Capital Advisors LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth $51,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of United Therapeutics by 49.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 65 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.